ClinicalTrialsFinder

Autosomal Recessive Polycystic Kidney (ARPKD) Clinical Trials in Chicago, Illinois

1 recruitingChicago, Illinois

Showing 1–1 of 1 trials

Recruiting
Phase 3

A Study to See if Tolvaptan is Safe in Infants and Children Who at Enrollment Are 28 Days to Less Than 18 Years Old With Autosomal Recessive Polycystic Kidney Disease (ARPKD)

Autosomal Recessive Polycystic Kidney (ARPKD)
Otsuka Pharmaceutical Development & Commercialization, Inc.20 enrolled23 locationsNCT04782258